Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7590414 | 1.00 | SIGMAR1 (0.43) | SIGMAR1OPRD1OPRM1SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL28404227 | 0.98 | SIGMAR1 (0.42) | SIGMAR1OPRD1OPRM1SLC6A4SLC6A2 | |
| SCHEMBL29926322 | 0.98 | SIGMAR1 (0.42) | SIGMAR1OPRD1OPRM1SLC6A4SLC6A2 | |
| SCHEMBL6423819 | 0.96 | SIGMAR1 (0.41) | SIGMAR1OPRD1OPRM1SLC6A4SLC6A2 | |
| SCHEMBL1607970 | 0.90 | OPRD1 (0.41) | SIGMAR1OPRD1OPRM1SLC6A4SLC6A2 | |
| SCHEMBL2910332 | 0.86 | OPRD1 (0.38) | SIGMAR1OPRD1OPRM1SLC6A4SLC6A2 | |
| SCHEMBL27667325 | 0.86 | SIGMAR1 (0.44) | SIGMAR1OPRD1OPRM1SLC6A4SLC6A2 | |
| SCHEMBL3102765 | 0.85 | — | — | |
| SCHEMBL29004649 | 0.85 | SIGMAR1 (0.48) | SIGMAR1SLC6A4SLC6A2CHRM3SLC6A3 | |
| SCHEMBL6658920 | 0.84 | SMN1; SMN2 (0.36) | SIGMAR1OPRD1OPRM1SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111592688-B | Piperazine based amide acid salt heat stabilizer for PVC, preparation method thereof and PVC composite material | 唐山师范学院 | 2022-03-22 | — | — | CN | disclosed |
| CN-111592688-A | Piperazine based amide acid salt heat stabilizer for PVC, preparation method thereof and PVC composite material | 唐山师范学院 | 2020-08-28 | — | — | CN | disclosed |
| EP-2667848-A1 | CARRIERS FOR THE LOCAL RELEASE OF HYDROPHILIC PRODRUGS | Koninklijke Philips N.V. (NL) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101587-A1 | CARRIERS FOR THE LOCAL RELEASE OF HYDROPHILIC PRODRUGS | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2012-08-02 | — | — | WO | disclosed |
| US-8207163-B2 | Compositions, synthesis, and methods of using piperazine based antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2299814-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS | Reviva Pharmaceuticals, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009154993-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| EP-1349841-B1 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7553969-B1 | Substituted phenethylamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2003-10-30 | — | — | US | disclosed |
| EP-1349841-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-1349840-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002046171-A2 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046170-A2 | ANILINOPYRIMIDINE DERIVATIVES AS JNK PATHWAY INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| EP-1149843-A1 | SUBSTITUTED PHENETHYLAMINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-10-31 | — | — | EP | disclosed |
| US-5948911-A | Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 1999-09-07 | — | — | US | disclosed |
| US-5215974-A | Antisecretory agents for gastrointestinal disorders; water solubility, chemical stability | AKTIEBOLAGET HASSLE (SE) | 1993-06-01 | — | — | US | disclosed |
| EP-0332647-A1 | NEW BENZIMIDAZOLE DERIVATIVES A PROCESS FOR PRODUCTION THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Aktiebolaget Hässle (SE) | 1989-09-20 | — | — | EP | disclosed |
| WO-1988003921-A1 | NEW BENZIMIDAZOLE DERIVATIVES A PROCESS FOR PRODUCTION THEREOF AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Aktiebolaget Hässle (SE) | 1988-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | GRIK5, GAP43, GRIN2D | SIGMAR1 2664/4885OPRD1 1474/4885OPRM1 2474/4885 |
| US-20030203926-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | NFKBIA, IKBKB, IKBKE | SIGMAR1 4202/4885OPRD1 1817/4885OPRM1 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.